Where to deliver the biontech vaccine in the netherlands?

Asked By: Kyra Ferry
Date created: Sun, Mar 7, 2021 7:40 AM
Best answers
Pfizer/BioNTech will increase its Covid-19 vaccine deliveries to the Netherlands by sending between 144,000 and 230,000 extra doses to the Netherlands every week starting at the end of April. The increase is in addition to the weekly delivery of a half-million doses already planned, and should scale up towards a million doses weekly, NOS reported.
Answered By: Danial Kub
Date created: Tue, Mar 9, 2021 6:05 AM
The first 500,000 doses of the BioNTech/Pfizer vaccine are expected to be delivered to the Netherlands before the end of this year. Delivery is expected shortly after the European Commission’s decision on marketing authorisation. The definitive delivery schedule is currently being finalised with the supplier. Major expansion in communications
Answered By: Micah Schowalter
Date created: Thu, Mar 11, 2021 2:42 PM
The Netherlands expects to take delivery of 61.7 million coronavirus vaccine doses by the end of March 2022. Delivery began with the Pfizer/BioNTech vaccine in December 2020, when the country received its first 165 thousand doses.
Answered By: Paula Rice
Date created: Sat, Mar 13, 2021 12:45 AM
BioNTech SE facility in Marburg, is a key piece of a plan by the German company and partner Pfizer Inc. to boost production of their shot to 2 billion doses this year.
Answered By: Shirley Konopelski
Date created: Mon, Mar 15, 2021 7:40 AM
UPS has built two freezer farms, one in the Netherlands and one in the US, to house a total of 600 deep-freezers that can each hold 48,000 vials of vaccine at temperatures as low as -80C.
Answered By: Hermina Murphy
Date created: Mon, Mar 15, 2021 2:43 PM
Currently, the Netherlands plans a gap of 12 weeks between the two doses of the AstraZeneca vaccine, but this could be easily stretched to 24 weeks, Van der Zeijst said. Talks Dutch health ministry officials say they are due to talk to AstraZeneca about the first quarter delivery schedule next week.
Answered By: Leopold Carroll
Date created: Tue, Mar 16, 2021 12:53 PM
The EU’s drug regulator gave the green light for the Pfizer-BioNTech coronavirus vaccine on Monday, and said there was no evidence it would not work against a new strain spreading in Britain. The European Medicines Agency said the “historic” step paved the way for vaccinations to finally start within days across the 27-nation EU where cases of the disease are surging.
Answered By: Annamae Rodriguez
Date created: Wed, Mar 17, 2021 2:25 PM
The Hague, Netherlands: The EU's drug regulator authorised the Pfizer-BioNTech coronavirus vaccine on Monday, and said there was no evidence it would not work against a new strain found mainly in ...
Answered By: Valerie Larson
Date created: Fri, Mar 19, 2021 9:54 PM
Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses. Download PDF Copy. By Sally Robertson, B.Sc. May 10 2021. Researchers in The Netherlands and Germany have ...
Answered By: Sabina Schuster
Date created: Mon, Mar 22, 2021 12:05 AM
The shot - using the hitherto unproven mRNA method to deliver vaccines - has since proven a success in public rollouts across the world. In March, BioNTech even promised 2.5 billion doses this ...
Answered By: Narciso Roob
Date created: Tue, Mar 23, 2021 7:19 PM
Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine: The Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) recommended that use of (J&J/Janssen) COVID-19 Vaccine resume in the United States, effective April 23, 2021. However, women younger than 50 years old should especially be aware of the rare risk of blood clots with low platelets after ...
Updated 25 June 2021, pursuant to updated interim recommendations . WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has issued its policy recommendations for the rollout of the first COVID-19 vaccine approved for emergency use, the Pfizer-BioNTech COVID-19 vaccine. According to SAGE, the Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective.
CureVac initiates a Phase 2a clinical trial of its COVID-19 vaccine candidate in Peru and Panama. Early September 2020. CureVac receives a grant of up to 252 million euros from the German Federal Ministry of Education and Research to further its COVID-19 vaccine development and expand its production capacity.
The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued Interim recommendations for the use of the inactivated COVID-19 vaccine, Sinovac-CoronaVac, developed by Sinovac/China National Pharmaceutical Group.. Here is what you need to know. This article provides a summary of the interim recommendations; the interim recommendations and the background document are also ...
The coronavirus, which first sickened people in China in December, is thought to have passed from animals to humans, like many similar pathogens, but nothing has been confirmed yet by any...
For the first time since March 2020, the country is averaging fewer than 300 coronavirus deaths each day. The highly infectious Delta variant continues to spread, driving up case totals in parts of...
How Well the Vaccine Works. Based on evidence from clinical trials in people 16 years and older, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.; In clinical trials, the Pfizer-BioNTech vaccine was also highly effective at preventing ...
58 similar questions